Netramark signs four AI contracts with pharma company

Executive Summary

• Netramark Holdings Inc. has signed four new contracts with a leading global pharmaceutical company to provide AI-driven analytics for late-stage clinical trials.
• The agreements utilize Netramark's proprietary NetraAI platform to analyze clinical data from four pivotal studies, aiming to identify patient subpopulations and characterize treatment/placebo responses.
• The contracts were executed under an existing master services agreement, signaling continued confidence in Netramark's technology and expanding their ongoing collaboration with the sponsor.

Key Details

• Contract Volume: Four new contracts signed with a single leading global pharmaceutical company.
• Technology Applied: Netramark's proprietary NetraAI platform, described as a mathematically augmented AI system with focus mechanisms to separate data into explainable and unexplainable subsets.
• Scope of Work:
  • Application of NetraAI to clinical data from four pivotal (late-stage) studies.
  • Conducting multistudy analyses to identify explainable subpopulations characterizing treatment and placebo response patterns.
  • Quantifying clinical and demographic variables influencing variability in study outcomes.
• Strategic Value:
  • Enhances understanding of complex patient populations.
  • Aims to increase clinical trial success chances by avoiding overfitting common in other AI methods.
  • Aligns with FDA expectations for explainable AI methods in clinical development.
• Contract Structure: Executed under an existing master services agreement, representing new discrete projects within a continuing engagement.

Notable Quotes

• "The signing of these four contracts represents a significant expansion of our ongoing collaboration with a leading pharmaceutical company," said George Achilleos, chief executive officer of Netramark. "Our NetraAI system seeks to generate explainable insights from complex, heterogeneous clinical data sets -- enabling sponsors to better understand their patient populations and make more informed development decisions."